false
0000827871
0000827871
2024-02-29
2024-02-29
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND
EXCHANGE COMMISSION
Washington, D.C.
20549
FORM 8-K
CURRENT REPORT
Pursuant to Section
13 or 15(d)
of the Securities
Exchange Act of 1934
Date of Report (Date of
earliest event reported): February 29,
2024
Eagle Pharmaceuticals, Inc.
(Exact name of registrant
as specified in its charter)
Delaware |
001-36306 |
20-8179278 |
(State
or other jurisdiction of |
(Commission File Number) |
(IRS Employer Identification No.) |
incorporation) |
|
|
50 Tice Boulevard, Suite 315
Woodcliff Lake, NJ |
|
07677 |
(Address of principal executive offices) |
|
(Zip Code) |
Registrant’s
telephone number, including area code: (201) 326-5300
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:
¨ Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities
registered pursuant to Section 12(b) of the Act:
Title of each class |
|
Trading
Symbol |
|
Name
of each exchange on which registered |
Common Stock (par value $0.001 per share) |
|
EGRX |
|
The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange
Act of 1934 (17 CFR §240.12b-2).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 1.01 | Entry Into a Material Definitive Agreement. |
On February 29, 2024
(the “Amendment Date”), Eagle Pharmaceuticals, Inc. (the “Company”), entered into a Second Amendment to Third
Amended and Restated Credit Agreement (the “Second Amendment Agreement”) with JPMorgan Chase Bank, N.A., as administrative
agent (the “Agent”), and the lenders party thereto (the “Lenders”), which amends the terms of (i) the Company’s
Third Amended and Restated Credit Agreement, dated as of November 1, 2022 (the “Original Credit Agreement”) and (ii) the Limited
Waiver and First Amendment to Third Amended and Restated Credit Agreement, dated as of January 12, 2024 (the “First Amendment Agreement”).
The Original Credit Agreement as amended by the First Amendment Agreement is referred to herein as the “Credit Agreement,”
and the Credit Agreement as amended by the Second Amendment Agreement is referred to herein as the “Amended Credit Agreement.”
As previously disclosed
in the Company’s Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission (the “SEC”) on January
16, 2024, incorporated by reference herein, the Company, the Agent and the Lenders entered into the First Amendment Agreement, which provided
a waiver of defaults and events of default that occurred and were continuing under Original Credit Agreement at such time.
Pursuant to the Credit
Agreement and the First Amendment, (i) the Company is required to deliver to the Agent and the Lenders, by not later than March 30, 2024,
annual audited financial statements for the fiscal year ended December 31, 2024, reported on by the Company’s independent public
accountant (without a “going concern” or like qualification or exception and without any qualification or exception as to
the scope of such audit) to the effect that such consolidated financial statements present fairly in all material respects the financial
condition and results of operations of the Company and its consolidated subsidiaries in accordance with GAAP (the “Annual Financial
Statement Requirement”), (ii) the Company is required to deliver to the Agent and the Lenders, by not later than February 29, 2024,
(a) restated quarterly financial statements for the fiscal quarter ended June 30, 2023 and (b) quarterly financial statements for the
fiscal quarter ended September 30, 2023, in each case with respect to this clause (ii), certified by one of its officers as presenting
fairly in all material respects the financial condition and results of operations of the Company and its consolidated subsidiaries in
accordance with GAAP for the respective quarter (this clause (ii), the “Quarterly Financial Statement Requirement” and together
with the Annual Financial Statement Requirement, the “Financial Statement Requirement”) and (iii) until the Quarterly Financial
Statement Requirement has been satisfied, (a) availability under the Credit Agreement is reduced from $100 million to $50 million, (b)
the Company is not permitted to utilize any negative covenant flexibility that is based on a pro forma compliance with any of the Fixed
Charge Coverage Ratio, Senior Secured Net Leverage Ratio and/or the Total Net Leverage Ratio test (each as defined in the Credit Agreement),
which restricts the Company’s flexibility to, among other things, incur certain additional indebtedness, complete certain corporate
transactions, including certain acquisitions and dispositions, or make certain additional restricted payments and (c) compliance with
the minimum liquidity covenant is waived (the restrictions described in this clause (iii), the “Temporary Restrictions”).
Pursuant to the terms
of the Second Amendment Agreement, (i) the delivery deadline with respect to each Financial Statement Requirement has been extended to
May 13, 2024 and (ii) the Temporary Restrictions have been revised to continue until the Company has satisfied the Annual Financial Statement
Requirement in addition to the Quarterly Financial Statement Requirement.
Pursuant to the terms
of the Amended Credit Agreement, failure to timely satisfy the Financial Statement Requirement will result in an event of default. During
the continuance of an event of default, the Agent may, with the consent of the required lenders, and shall, at the request of the required
lenders, by notice to the Company, terminate undrawn commitments, declare the loans then outstanding to be due and payable in full and/or
exercise other remedies available to it, among other things. In addition, the Company’s obligations under the Amended Credit Agreement
are secured by a pledge of substantially all of the Company’s assets. If the Company is unable to pay its obligations, the Agent
on behalf of the lenders could proceed to protect and enforce their rights under the Amended Credit Agreement, including by foreclosure
on the assets securing the Company’s obligations under the Amended Credit Agreement. The foregoing would materially and adversely
affect the Company’s business and financial condition. There can be no assurance that the Company will be able to satisfy the Financial
Statement Requirement on the required timing or at all, or comply with the terms of the Second Amendment Agreement and the Amended Credit
Agreement.
The foregoing descriptions
of the Second Amendment Agreement, the First Amendment Agreement and the Original Credit Agreement are not intended to be complete and
are qualified in their entirety by reference to the full text of the Second Amendment Agreement, the First Amendment Agreement and the
Original Credit Agreement, which are filed as Exhibit 10.1 to this Current Report on Form 8-K, Exhibit 10.1 to the Company’s Current
Report on Form 8-K filed on January 16, 2024, and Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on November 3,
2022, respectively.
Forward-Looking Statements
This current report on
Form 8-K contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995,
as amended, and other securities law. Forward-looking statements are statements that are not historical facts. Words and phrases such
as “anticipated,” “forward,” “will,” “would,” “could,” “may,”
“intend,” “remain,” “potential,” “prepare,” “expected,” “believe,”
“plan,” “seek,” “continue,” “estimate,” “and similar expressions are intended to
identify forward-looking statements. These statements include, but are not limited to, statements with respect to: the Company’s
expectations with respect to the Amended Credit Agreement and the Second Amendment Agreement and its ability to satisfy the Financial
Statement Requirement on the required timing or at all, and otherwise comply with the Amended Credit Agreement and the Second Amendment
Agreement, the potential actions that the Agent on behalf of the lenders could take to protect and enforce their rights under the Amended
Credit Agreement, and the expected filing of an amendment to the Company’s Form 10-Q for the quarter ended June 30, 2023, a Form
10-Q for the quarter ended September 30, 2023 and a Form 10-K for the year ended December 31, 2023. All of such statements are subject
to certain risks and uncertainties, many of which are difficult to predict and generally beyond the Company’s control, that could
cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements.
Such risks and uncertainties include, but are not limited to: the completion of the review and preparation of the Company’s financial
statements and internal control over financial reporting and disclosure controls and procedures and the timing thereof; the discovery
of additional information; further delays in the Company’s financial reporting, including as a result of unanticipated factors;
the Company’s ability to comply with its obligations under its credit agreement; the possibility that the Company will be unable
to regain compliance with, or thereafter continue to comply with, the Nasdaq Listing Rules, or experience violations of additional Nasdaq
Listing Rules; the possibility that the Nasdaq may delist the Company’s securities; the Company’s ability to remediate material
weaknesses in its internal control over financial reporting; the Company’s ability to recruit and hire a new Chief Executive Officer;
the ability of the Company to realize the anticipated benefits of its plan designed to improve operational efficiencies and realign its
sales and marketing expenditures and the potential impacts thereof; the impacts of the post- COVID-19 environment and geopolitical factors
such as the conflicts between Russia and Ukraine and Gaza and Israel; delay in or failure to obtain regulatory approval of the Company’s
or its partners’ product candidates and successful compliance with Federal Drug Administration, European Medicines Agency and other
governmental regulations applicable to product approvals; changes in the regulatory environment; the uncertainties and timing of the regulatory
approval process; whether the Company can successfully market and commercialize its products; the success of the Company's relationships
with its partners; the outcome of litigation; the strength and enforceability of the Company’s intellectual property rights or the
rights of third parties; competition from other pharmaceutical and biotechnology companies and competition from generic entrants into
the market; unexpected safety or efficacy data observed during clinical trials; clinical trial site activation or enrollment rates that
are lower than expected; the risks inherent in drug development and in conducting clinical trials; risks inherent in estimates or judgments
relating to the Company’s critical accounting policies, or any of the Company’s estimates or projections, which may prove
to be inaccurate; unanticipated factors in addition to the foregoing that may impact the Company’s financial and business projections
and guidance and may cause the Company’s actual results and outcomes to materially differ from its estimates, projections and guidance;
and those risks and uncertainties identified in the “Risk Factors” sections of the Company’s Annual Report on Form 10-K
for the year ended December 31, 2022, filed with the SEC on March 23, 2023, the Company’s Quarterly Reports on Form 10-Q for the
quarter ended March 31, 2023, filed with the SEC on May 9, 2023, and for the quarter ended June 30, 2023, filed with the SEC on August
8, 2023, and its other subsequent filings with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements.
All forward-looking statements contained in this current report on Form 8-K speak only as of the date on which they were made. Except
to the extent required by law, the Company undertakes no obligation to update such statements to reflect events that occur or circumstances
that exist after the date on which they were made.
Item 9.01 |
Financial Statements and Exhibits. |
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: March 1, 2024 |
EAGLE PHARMACEUTICALS, INC. |
|
|
|
By: |
/s/ Brian Cahill |
|
|
Brian Cahill |
|
|
Chief Financial Officer |
Exhibit 10.1
EXECUTION VERSION
SECOND AMENDMENT TO THIRD AMENDED AND RESTATED
CREDIT AGREEMENT
This SECOND AMENDMENT TO THIRD
AMENDED AND RESTATED CREDIT AGREEMENT (this “Agreement”) is made as of February 29, 2024 by and among Eagle Pharmaceuticals,
Inc., a Delaware corporation (the “Borrower”), the financial institutions listed on the signature pages hereto and
JPMorgan Chase Bank, N.A., as Administrative Agent (the “Administrative Agent”), in connection with that certain Third
Amended and Restated Credit Agreement, dated as of November 1, 2022, by and among the Borrower, the Lenders and the Administrative Agent
(as further amended, restated, supplemented or otherwise modified from time to time, the “Credit Agreement”). Capitalized
terms used herein and not otherwise defined herein shall have the respective meanings given to them in the Credit Agreement.
WHEREAS, the Borrower, the
Lenders party thereto and the Administrative Agent have entered into that certain Limited Waiver and First Amendment to Third Amended
and Restated Credit Agreement, dated as of January 12, 2024 (the “First Amendment”).
WHEREAS, the Borrower has
requested that the requisite Lenders and the Administrative Agent agree to make certain amendments to the Credit Agreement and the First
Amendment.
WHEREAS, the Borrower, the
Lenders party hereto and the Administrative Agent have so agreed on the terms and conditions set forth herein.
NOW, THEREFORE, in consideration
of the premises set forth above, the terms and conditions contained herein, and other good and valuable consideration, the receipt and
sufficiency of which are hereby acknowledged, the Borrower, the Lenders party hereto and the Administrative Agent hereby agree as follows:
1.
Amendments to the Credit Agreement and First Amendment.
(a)
Effective as of the date hereof, the Credit Agreement is hereby amended as follows:
(i) Section 5.01(a)
of the Credit Agreement is hereby deleted in its entirety and replaced with the following:
“(a) (x) with
respect to the fiscal year of the Borrower ended December 31, 2023, no later than May 13, 2024 and (y) within ninety (90) days after the
end of each other fiscal year of the Borrower, its audited consolidated balance sheet and related statements of operations, stockholders’
equity and cash flows as of the end of and for such year, setting forth in each case in comparative form the figures for the previous
fiscal year, all reported on by BDO USA, LLP or other independent public accountants of recognized national standing (without a “going
concern” or like qualification or exception and without any qualification or exception as to the scope of such audit) to the effect
that such consolidated financial statements present fairly in all material respects the financial condition and results of operations
of the Borrower and its consolidated Subsidiaries on a consolidated basis in accordance with GAAP consistently applied;”
(ii) Section 5.01(b)
of the Credit Agreement is hereby deleted in its entirety and replaced with the following:
“(b) (i) (x)
with respect to the fiscal quarter of the Borrower ended September 30, 2023, no later than May 13, 2024 and (y) with respect to each
other of the first three fiscal quarters of each fiscal year of the Borrower, within forty-five (45) days after the end of each
such fiscal quarter, its consolidated balance sheet and related statements of operations, stockholders’ equity and cash flows
as of the end of and for such fiscal quarter and the then elapsed portion of the fiscal year, setting forth in each case in
comparative form the figures for the corresponding period or periods of (or, in the case of the balance sheet, as of the end of) the
previous fiscal year, all certified by one of its Financial Officers as presenting fairly in all material respects the financial
condition and results of operations of the Borrower and its consolidated Subsidiaries on a consolidated basis in accordance with
GAAP consistently applied, subject to normal year-end audit adjustments and the absence of footnotes; and
(ii) no later than May
13, 2024, a restatement of the financial statements previously delivered pursuant to Section 5.01(b) of this Agreement for the fiscal
quarter ended June 30, 2023, certified by one of its Financial Officers as presenting fairly in all material respects the financial condition
and results of operations of the Borrower and its consolidated Subsidiaries on a consolidated basis in accordance with GAAP consistently
applied, subject to normal year-end audit adjustments and the absence of footnotes, for the avoidance of doubt, accompanied by a certificate
satisfying the requirements of Section 5.01(c) for such fiscal quarter;”
(b)
Effective as of the date hereof, the introductory portion of the first sentence of Section 2(b) of the First Amendment (preceding
clauses (i) through (iii) of such Section 2(b)) is hereby deleted in its entirety and replaced with the following:
“(b) From and
after the date hereof until the date on which the Borrower delivers (i) (x) all financial reporting materials required by Section 5.01(b)
of the Credit Agreement and (y) the certificate required by Section 5.01(c) of the Credit Agreement, in each case with respect to the
fiscal quarters of the Borrower ended June 30, 2023 and September 30, 2023 and (ii) (x) all financial reporting materials required by
Section 5.01(a) of the Credit Agreement and (y) the certificate required by Section 5.01(c) of the Credit Agreement, in each case with
respect to the fiscal year of the Borrower ended December 31, 2023 (such date, the “Updated Financials Delivery Date”):”
2.
Conditions of Effectiveness. The effectiveness of this Agreement is subject to the satisfaction of the following
conditions precedent:
(a)
The Administrative Agent shall have received counterparts of this Agreement duly executed by the Borrower, the Required Lenders
and the Administrative Agent, and the Consent and Reaffirmation attached hereto as Annex I duly executed by each Subsidiary Guarantor
(the “Reaffirmation”).
(b)
The Administrative Agent shall have received payment of fees (if any) and its reasonable and documented out-of-pocket expenses
in connection with this Agreement.
3.
Representations and Warranties of the Borrower. The Borrower hereby represents and warrants as follows:
(a)
This Agreement and the Credit Agreement and First Amendment (each as amended hereby) constitute legal, valid and binding obligations
of the Borrower, enforceable in accordance with their terms, subject to applicable bankruptcy, insolvency, reorganization, moratorium
or other laws affecting creditors’ rights generally and subject to general principles of equity, regardless of whether considered
in a proceeding in equity or at law.
(b)
As of the date hereof, after giving effect to the terms of this Agreement, (i) the representations and warranties of the Borrower
set forth in the Credit Agreement and the First Amendment (each as amended hereby) are true and correct in all material respects (or,
if qualified by materiality or “Material Adverse Effect”, in all respects) as of the date hereof, except in the case of any
such representation and warranty that expressly relates to an earlier date, in which case such representation and warranty was true and
correct in all material respects (or, if qualified by materiality or “Material Adverse Effect”, in all respects) as of such
earlier date and (ii) no Default or Event of Default has occurred and is continuing.
4.
Reference to and Effect on the Credit Agreement and First Amendment.
(a)
Upon the effectiveness hereof, each reference to the Credit Agreement or the First Amendment in the Credit Agreement, the First
Amendment or any other Loan Document shall mean and be a reference to the Credit Agreement or the First Amendment, respectively, as amended
hereby.
(b) The
Credit Agreement, the First Amendment and all other documents, instruments and agreements executed and/or delivered in connection therewith
shall remain in full force and effect and are hereby ratified and confirmed. The Borrower (i) agrees that, except as specifically
provided herein, this Agreement and the transactions contemplated hereby shall not limit or diminish the obligations of the Borrower
arising under or pursuant to the Credit Agreement, the First Amendment or the other Loan Documents to which it is a party and acknowledges
that the limitations and pricing set forth in Sections 2(b) and 2(c), respectively, of the First Amendment remain in full
force and effect, (ii) reaffirms its obligations under the Credit Agreement, the First Amendment the Security Agreement and each
and every other Loan Document to which it is a party and (iii) reaffirms all Liens on the Collateral which have been granted by
it in favor of the Administrative Agent (for itself and the other Secured Parties) pursuant to any of the Loan Documents and all filings
made with any Governmental Authority in connection with such Liens. Without in any way limiting the foregoing, this Agreement shall not
constitute a novation of the Loan Documents or any Obligations or Secured Obligations.
(c)
Except with respect to the subject matter hereof, the execution, delivery and effectiveness of this Agreement shall not operate
as a waiver of any right, power or remedy of the Administrative Agent or the Lenders (including in connection with any Default or Event
of Default), nor constitute a waiver of any provision of the Credit Agreement, the First Amendment or any other documents, instruments
and agreements executed and/or delivered in connection therewith (or any Default or Event of Default thereunder).
(d)
This Agreement and the Reaffirmation are Loan Documents.
5.
Governing Law. This Agreement shall be construed in accordance with and governed by the law of the State of New York.
6.
Headings. Section headings in this Agreement are included herein for convenience of reference only and shall not
constitute a part of this Agreement for any other purpose.
7. Counterparts. This Agreement may be executed by one or more of the parties hereto on any number of separate counterparts,
and all of said counterparts taken together shall be deemed to constitute one and the same instrument. Delivery of an executed counterpart
of a signature page of this Agreement by telecopy, emailed .pdf or any other electronic means that reproduces an image of the actual
executed signature page shall be effective as delivery of a manually executed counterpart of this Agreement. For the avoidance of doubt,
the provisions of Section 9.06(b) of the Credit Agreement apply to this Amendment.
[Signature Pages
Follow]
IN WITNESS WHEREOF, this Agreement
has been duly executed as of the day and year first above written.
|
EAGLE PHARMACEUTICALS, INC., |
|
as the Borrower |
|
|
|
|
By: |
/s/ Brian Cahill |
|
Name: |
Brian Cahill |
|
Title: |
Chief Financial Officer |
Signature Page to Second Amendment to
Third Amended and Restated Credit Agreement
Eagle Pharmaceuticals, Inc.
|
JPMORGAN CHASE BANK, N.A., |
|
individually as a Lender and as Administrative Agent |
|
|
|
|
By: |
/s/ David Hyman |
|
Name: |
David Hyman |
|
Title: |
Authorized Signer |
Signature Page to Second Amendment to
Third Amended and Restated Credit Agreement
Eagle Pharmaceuticals, Inc.
|
CITIZENS BANK, N.A., |
|
as a Lender |
|
|
|
|
By: |
/s/ Benjamin Sileo |
|
Name: |
Benjamin Sileo |
|
Title: |
VP |
Signature Page to Second Amendment to
Third Amended and Restated Credit Agreement
Eagle Pharmaceuticals, Inc.
|
FIFTH THIRD BANK, NATIONAL ASSOCIATION, |
|
as a Lender |
|
|
|
|
By: |
/s/ Andy Reidell |
|
Name: |
Andy Reidell |
|
Title: |
Executive Director |
Signature Page to Second Amendment to
Third Amended and Restated Credit Agreement
Eagle Pharmaceuticals, Inc.
|
FIRST NATIONAL BANK OF PENNSYLVANIA, |
|
as a Lender |
|
|
|
|
By: |
/s/ Dave Diez |
|
Name: |
Dave Diez |
|
Title: |
Managing Director of Debt Capital Markets |
Signature Page to Second Amendment to
Third Amended and Restated Credit Agreement
Eagle Pharmaceuticals, Inc.
|
BARCLAYS BANK PLC, |
|
as a Lender |
|
|
|
|
By: |
/s/ Warren Veech III |
|
Name: |
Warren Veech III |
|
Title: |
Vice President |
Signature Page to Second Amendment to
Third Amended and Restated Credit Agreement
Eagle Pharmaceuticals, Inc.
ANNEX I
CONSENT AND REAFFIRMATION
Each of the undersigned hereby
acknowledges receipt of a copy of the foregoing Second Amendment, dated as of the date hereof, in connection with the Third Amended and
Restated Credit Agreement, dated as of November 1, 2022 (as amended, restated, supplemented or otherwise modified, the “Credit
Agreement”) by and among Eagle Pharmaceuticals, Inc., a Delaware corporation (the “Borrower”), the financial
institutions from time to time party thereto (the “Lenders”) and JPMorgan Chase Bank, N.A., as Administrative Agent
(the “Administrative Agent”) (the “Amendment”). Capitalized terms used in this Consent and Reaffirmation
and not defined herein shall have the meanings given to them in the Credit Agreement. Without in any way establishing a course of dealing
by the Administrative Agent or any Lender, each of the undersigned (a) consents to the Amendment and reaffirms the terms and conditions
of the Credit Agreement and any other Loan Document executed by it and acknowledges and agrees that such Credit Agreement and each and
every such Loan Document executed by the undersigned in connection with the Credit Agreement remains in full force and effect and is hereby
reaffirmed, ratified and confirmed, (b) reaffirms its obligations under the each and every Loan Document to which it is a party (including,
without limitation, each applicable Collateral Document) and (c) reaffirms all Liens on the Collateral which have been granted by it in
favor of the Administrative Agent (for itself and the other Secured Parties) pursuant to any of the Loan Documents and any filings made
with a Governmental Authority in connection therewith. All references to the Credit Agreement contained in the above-referenced documents
shall be a reference to the Credit Agreement as so modified by the Amendment.
Dated: February 29, 2024
[Signature
Page Follows]
|
EAGLE BIOLOGICS, INC. |
|
|
|
By: |
/s/ Brian Cahill |
|
Name: |
Brian Cahill |
|
Title: |
Chief Financial Officer |
|
|
|
EAGLE RESEARCH LABS LIMITED |
|
|
|
By: |
/s/ Brian Cahill |
|
Name: |
Brian Cahill |
|
Title: |
Director |
|
|
|
ACACIA PHARMA INC. |
|
|
|
By: |
/s/ Ryan Debski |
|
Name: |
Ryan Debski |
|
Title: |
Secretary |
|
|
|
ACACIA PHARMA GROUP LIMITED |
|
|
|
By: |
/s/ Ryan Debski |
|
Name: |
Ryan Debski |
|
Title: |
Director |
|
|
|
ACACIA PHARMA LIMITED |
|
|
|
By: |
/s/ Ryan Debski |
|
Name: |
Ryan Debski |
|
Title: |
Director |
|
|
|
ACACIA PHARMA IRELAND LIMITED |
|
|
|
By: |
/s/ Ryan Debski |
|
Name: |
Ryan Debski |
|
Title: |
Director |
Signature Page to Consent and Reaffirmation
Second Amendment to Third Amended and Restated Credit Agreement
Eagle Pharmaceuticals, Inc.
v3.24.0.1
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 2 such as Street or Suite number
+ References
+ Details
Name: |
dei_EntityAddressAddressLine2 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Section 14a -Number 240 -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
Eagle Pharmaceuticals (NASDAQ:EGRX)
Historical Stock Chart
From Jul 2024 to Aug 2024
Eagle Pharmaceuticals (NASDAQ:EGRX)
Historical Stock Chart
From Aug 2023 to Aug 2024